Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B

By Ting Chang, Ching‐lung Lai, Seung Kew Yoon, Samuel S. Lee, H. Coelho, F. Carrilho, F. Poordad, W. Halota, Y. Horsmans, N. Tsai and 4 more. Hepatology, 2010

601 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology, Surgery

View Paper: https://www.semanticscholar.org/paper/32a0f5de9c0b5056f4c30365d71349c6dd3a72af

Citations in the corpus

• EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. (2012, background): “Entecavir and tenofovir are potent HBV inhibitors with a high barrier to resistance [67,70,78,85,92,123] (Fig.”